ADAG
Neutral signalScored 2026-09-20 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Adagene Inc.
- Nom
- Adagene Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $90.7M
- Employés
- 128
- PDG
- Peter Luo
- Site web
- https://www.adagene.com
- Marché
- ACETCRVOFBIOGANXLITSNRXP
Adagene Inc. functions as a clinical-stage biopharmaceutical organization, primarily concentrating on the identification, evolution, and fabrication of monoclonal antibody-based therapeutics engineered to combat various types of cancer. The company's developmental pipeline encompasses several investigational assets currently undergoing human trials. Among these is ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibody, which is navigating Phase 1b/2 clinical assessment for individuals with advanced solid tumors and non-Hodgkin's lymphoma. Additionally, Adagene is progressing ADG126, a fully-human anti-CTLA-4 mAb, and ADG116, another human ligand-blocking anti-CTLA-4 mAb, both of which are advancing through Phase 1 studies for the treatment of advanced or metastatic solid tumors. Further along, ADG104, an anti-PD-L1 mAb, is in Phase 2 clinical development, and the innovative anti-CSF-1R mAb, ADG125, is undergoing Phase 1 trials. Beyond its clinical-stage programs, the firm also maintains an active preclinical portfolio. This includes ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is being explored for hematologic and solid tumor indications; ADG138, a novel HER2xCD3 POWERbody designed to target HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody under investigation for its potential to minimize off-tumor toxicities. Adagene Inc. was founded in 2011 and its principal operations are based in Suzhou, China.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 23245 titres (~84764 USD)
- Insiders
- Luo Peter
- Total bought
-
$84,764
Avg buy (VWAP, 90d window) $3.43 vs last close $3.23 (-5.9%)
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-08-05
- Liquidity
- Illiquid $657,479/day · 20d vol
- Last synced
-
2026-10-20 00:36:23
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-23 | Tam Man Kin | Buy · P | 2,000 | $3.00 | $6,000 | Form 4 |
| 2026-09-16 | Luo Peter | Buy · P | 20,290 | $3.15 | $63,980 | Form 4 |
| 2026-08-14 | DO CUONG V | Buy · P | 2,000 | $3.75 | $7,500 | Form 4 |
| 2026-08-05 | Luo Peter | Buy · P | 279 | $3.65 | $1,018 | Form 4 |
| 2026-08-04 | Luo Peter | Buy · P | 22,966 | $3.65 | $83,746 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-09-20 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
ADAG presents a deeply distressed financial profile with a liquidity score of 45 and a fundamentals trend score of only 25, reflecting persistent cash burn, negative operating margins, and no clear path to commercial…
The first sentence of the analysis written for ADAG on 2026-09-20 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 3.07 · operating margin -279% — readings disagree
Suggested stop 2.65, nearest stored support minus 0.5 ATR(18.1% under the last close). Reward/risk to the next stored resistance is 1.14. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 100.0% | -797.5% | 100.0% | 100.0% | 100.0% | |
| Ebit Margin | -227.4% | -31578.0% | -89.2% | -848.2% | -698.9% | |
| Ebitda Margin | -219.7% | -30680.5% | -82.5% | -832.6% | -687.8% | |
| Operating Profit Margin | -279.5% | -34835.4% | -131.0% | -903.1% | -711.2% | |
| Pretax Profit Margin | -233.4% | -32403.5% | -95.3% | -855.6% | -702.5% | |
| Continuous Operations Profit Margin | -229.6% | -32386.4% | -104.6% | -860.6% | -719.2% | |
| Net Profit Margin | -229.6% | -32386.4% | -104.6% | -860.6% | -719.2% | |
| Bottom Line Profit Margin | -229.6% | -32386.4% | -104.6% | -860.6% | -719.5% | |
| Current Ratio | 3.074 | 2.299 | 3.606 | 2.711 | 6.235 | |
| Quick Ratio | 3.074 | 2.299 | 3.606 | 2.711 | 6.235 | |
| Solvency Ratio | -0.397 | -0.839 | -0.393 | -1.133 | -2.187 | |
| Cash Ratio | 2.961 | 2.231 | 3.495 | 2.610 | 5.848 | |
| Price To Earnings Ratio | -4.086 | -2.095 | -3.509 | -0.573 | -3.527 | |
| Price To Earnings Growth Ratio | 0.080 | -0.029 | 0.046 | -0.524 | -0.012 | |
| Forward Price To Earnings Growth Ratio | 0.080 | -0.029 | 0.046 | -0.524 | -0.012 | |
| Price To Earnings Diluted Ratio | -4.086 | -2.095 | -3.591 | -0.573 | -3.527 | |
| Price To Earnings Diluted Growth Ratio | 0.080 | -0.027 | 0.047 | -0.524 | -0.012 | |
| Price To Book Ratio | 2.019 | 1.419 | 0.948 | 0.552 | 1.650 | |
| Price To Sales Ratio | 9.304 | 694.627 | 3.692 | 4.940 | 25.390 | |
| Price To Free Cash Flow Ratio | -4.553 | -2.411 | -2.343 | -0.931 | -5.626 | |
| Price To Operating Cash Flow Ratio | -4.558 | -2.414 | -2.350 | -0.944 | -5.951 | |
| Debt To Assets Ratio | 0.080 | 0.207 | 0.193 | 0.184 | 0.040 | |
| Debt To Equity Ratio | 0.177 | 0.366 | 0.316 | 0.337 | 0.048 | |
| Debt To Capital Ratio | 0.151 | 0.268 | 0.240 | 0.252 | 0.046 | |
| Long Term Debt To Capital Ratio | 0.031 | 0.008 | 0.161 | 0.145 | 0.019 | |
| Financial Leverage Ratio | 2.214 | 1.767 | 1.640 | 1.834 | 1.210 | |
| Working Capital Turnover Ratio | 0.151 | 0.002 | 0.206 | 0.074 | 0.093 | |
| Operating Cash Flow Ratio | -0.622 | -0.778 | -0.905 | -0.883 | -1.456 | |
| Operating Cash Flow Sales Ratio | -2.041 | -287.789 | -1.571 | -5.231 | -4.267 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | 1.001 | 1.003 | 1.014 | 1.058 | |
| Debt Service Coverage Ratio | -3.042 | -1.697 | -1.751 | -5.438 | -14.747 | |
| Interest Coverage Ratio | -46.290 | -42.203 | -21.411 | -121.041 | -198.933 | |
| Short Term Operating Cash Flow Coverage Ratio | -3.144 | -1.669 | -3.389 | -3.569 | -9.653 | |
| Operating Cash Flow Coverage Ratio | -2.500 | -1.606 | -1.276 | -1.738 | -5.797 | |
| Capital Expenditure Coverage Ratio | -918.164 | -884.484 | -334.716 | -70.356 | -17.297 | |
| Dividend Paid And Capex Coverage Ratio | -918.164 | -884.484 | -334.716 | -70.356 | -17.297 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -0.185 | -0.158 | 1.389 | 0.903 | -1.307 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 100.0% | ▲897.5% | ▲179.5% |
| Ebit Margin | -227.4% | ▲31350.6% | ▲6460.9% |
| Ebitda Margin | -219.7% | ▲30460.8% | ▲6280.9% |
| Operating Profit Margin | -279.5% | ▲34555.9% | ▲7092.6% |
| Pretax Profit Margin | -233.4% | ▲32170.0% | ▲6624.6% |
| Continuous Operations Profit Margin | -229.6% | ▲32156.9% | ▲6630.5% |
| Net Profit Margin | -229.6% | ▲32156.9% | ▲6630.5% |
| Bottom Line Profit Margin | -229.6% | ▲32156.9% | ▲6630.6% |
| Current Ratio | 3.074 | ▲0.775 | ▼-0.511 |
| Quick Ratio | 3.074 | ▲0.775 | ▼-0.511 |
| Solvency Ratio | -0.397 | ▲0.442 | ▲0.593 |
| Cash Ratio | 2.961 | ▲0.730 | ▼-0.468 |
| Price To Earnings Ratio | -4.087 | ▼-1.992 | ▼-1.328 |
| Price To Earnings Growth Ratio | 0.080 | ▲0.108 | ▲0.168 |
| Forward Price To Earnings Growth Ratio | 0.080 | ▲0.108 | ▲0.168 |
| Price To Earnings Diluted Ratio | -4.087 | ▼-1.992 | ▼-1.312 |
| Price To Earnings Diluted Growth Ratio | 0.080 | ▲0.107 | ▲0.167 |
| Price To Book Ratio | 2.019 | ▲0.600 | ▲0.701 |
| Price To Sales Ratio | 9.305 | ▼-685.322 | ▼-138.286 |
| Price To Free Cash Flow Ratio | -4.553 | ▼-2.143 | ▼-1.381 |
| Price To Operating Cash Flow Ratio | -4.559 | ▼-2.145 | ▼-1.315 |
| Debt To Assets Ratio | 0.080 | ▼-0.127 | ▼-0.061 |
| Debt To Equity Ratio | 0.177 | ▼-0.189 | ▼-0.072 |
| Debt To Capital Ratio | 0.150 | ▼-0.117 | ▼-0.041 |
| Long Term Debt To Capital Ratio | 0.031 | ▲0.023 | ▼-0.042 |
| Financial Leverage Ratio | 2.214 | ▲0.447 | ▲0.481 |
| Working Capital Turnover Ratio | 0.151 | ▲0.149 | ▲0.046 |
| Operating Cash Flow Ratio | -0.622 | ▲0.156 | ▲0.306 |
| Operating Cash Flow Sales Ratio | -2.041 | ▲285.748 | ▲58.139 |
| Free Cash Flow Operating Cash Flow Ratio | 1.001 | -0.000 | ▼-0.014 |
| Debt Service Coverage Ratio | -3.042 | ▼-1.345 | ▲2.293 |
| Interest Coverage Ratio | -46.290 | ▼-4.087 | ▲39.686 |
| Short Term Operating Cash Flow Coverage Ratio | -3.144 | ▼-1.475 | ▲1.141 |
| Operating Cash Flow Coverage Ratio | -2.500 | ▼-0.894 | ▲0.083 |
| Capital Expenditure Coverage Ratio | -918.164 | ▼-33.680 | ▼-473.161 |
| Dividend Paid And Capex Coverage Ratio | -918.164 | ▼-33.680 | ▼-473.161 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -0.185 | ▼-0.027 | ▼-0.313 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $71.4M | $71.7M | $66.9M | $45.9M | $258.4M | |
| Enterprise value | $3.1M | $5.0M | -$20.8M | -$69.9M | $91.5M | |
| EV / Sales | 0.41x | 48.33x | -1.15x | -7.52x | 8.99x | |
| EV / Op. cash flow | -0.20x | -0.17x | 0.73x | 1.44x | -2.11x | |
| EV / Free cash flow | -0.20x | -0.17x | 0.73x | 1.42x | -1.99x | |
| EV / EBITDA | -0.18x | -0.16x | 1.39x | 0.90x | -1.31x | |
| Net debt / EBITDA | 4.05x | 2.11x | 5.86x | 1.50x | 2.38x | |
| Current ratio | 3.07x | 2.30x | 3.61x | 2.71x | 6.24x | |
| Income quality | 0.89x | 0.89x | 1.50x | 0.61x | 0.59x | |
| Graham net-net | $1 | $1 | $2 | $2 | $5 | |
| Tax burden | 98.3% | 99.9% | 109.8% | 100.6% | 102.4% | |
| Interest burden | 102.7% | 102.6% | 106.9% | 100.9% | 100.5% | |
| Working capital | $52.2M | $49.6M | $82.0M | $94.2M | $156.1M | |
| Invested capital | $53.1M | $51.0M | $84.2M | $97.2M | $159.6M | |
| Return on assets | -22.5% | -37.4% | -16.4% | -52.5% | -38.6% | |
| Operating ROA | -25.6% | -35.1% | -17.7% | -49.1% | -52.9% | |
| Return on tangible assets | -22.5% | -37.4% | -16.4% | -52.5% | -38.6% | |
| Return on equity | -49.8% | -66.2% | -26.9% | -96.2% | -46.7% | |
| Return on invested capital | -36.2% | -52.0% | -25.5% | -75.5% | -44.1% | |
| Return on capital employed | -40.4% | -70.4% | -28.1% | -86.2% | -45.3% | |
| Earnings yield | -24.7% | -46.6% | -28.3% | -174.2% | -28.3% | |
| Free cash flow yield | -22.0% | -41.5% | -42.7% | -107.4% | -17.8% | |
| Capex / Op. cash flow | -0.1% | -0.1% | -0.3% | -1.4% | -5.8% | |
| Capex / Depreciation | 2.9% | 3.6% | 7.0% | 47.7% | 223.1% | |
| Capex / Sales | 0.2% | 32.5% | 0.5% | 7.4% | 24.7% | |
| SG&A / Sales | 92.2% | 7047.5% | 47.9% | 127.8% | 141.9% | |
| R&D / Sales | 287.2% | 27887.9% | 202.3% | 875.3% | 669.3% | |
| Stock comp / Sales | 48.8% | 4757.2% | 40.1% | 113.2% | 183.6% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 1d | 29d | 4d | 24d | 269d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 1d | 29d | 4d | 24d | 269d | |
| Cash conversion cycle | 1d | 29d | 4d | 24d | 269d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-10-19 Adagene (NASDAQ:ADAG) Stock Rating Reaffirmed as “Buy” by HC Wainwright Adagene (NASDAQ: ADAG - Get Free Report)''s stock had its "buy" rating reaffirmed by research analysts at HC Wainwright in a note issued to investors on Monday, MarketBeat.com reports. They presently have a $7.00 target price on the stock. HC Wainwright''s price target would suggest a potential upside of 219.63% from the company''s previous close. A
- 2026-10-18 Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 Catalysts Adagene (NASDAQ: ADAG) Chairman, CEO and Co-Founder Peter Luo outlined the clinical-stage biotechnology company''s antibody pipeline, its approach to masked therapies and upcoming development milestones during a discussion focused on its T-cell engager, or TCE, portfolio. Luo said Adagene''s development strategy centers on targeting tumors while limiting effects on healthy tissue through its SAFEbody platform. The
- 2026-10-16 Adagene Highlights SAFEbody Pipeline, ADG138 Clinical Launch and 2027 Catalysts Adagene NASDAQ: ADAG Chairman, CEO and Co-Founder Peter Luo outlined the clinical-stage biotechnology company''s antibody pipeline, its approach to masked therapies and upcoming development milestones during a discussion focused on its T-cell engager, or TCE, portfolio.
- 2026-10-14 Adagene to Participate in H.C. Wainwright 4th Annual Immune Cell Engager Virtual Conference SAN DIEGO and SUZHOU, China, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that Adagene''s Chief Executive Officer and President of R&D, Peter Luo, Ph.D., will participate in a fireside chat at the H.C.
- 2026-09-22 Adagene Announces NMPA Clearance of Investigational New Drug Application for ADG138, a Novel HER2xCD3 Double-Masked Bispecific T-Cell Engager Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026 ADG138 is a double-masked T-cell engager, applying Adagene''s proprietary SAFEbody® precision masking technology on both HER2 and CD3 binding sites to enable tumor-selective therapy with low systemic toxicity Preclinical data demonstrated robust tumor regression in tumor models refractory and/or resistant to Enhertu, along with strong synergy in combination with anti-CTLA-4, anti-PD-1 or anti-CD137 antibodies SAN DIEGO and SUZHOU, China, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that China''s National Medical Products Administration (NMPA) has approved the company''s investigational new drug (IND) application for ADG138, a double-masked HER2×CD3 bispecific T cell engager built on Adagene''s proprietary SAFEbody® precision masking technology.
- 2026-09-20 Insider Buying: Adagene (NASDAQ:ADAG) CEO Acquires $63,913.50 in Stock Adagene Inc. Sponsored ADR (NASDAQ: ADAG - Get Free Report) CEO Peter Luo acquired 20,290 shares of the business''s stock in a transaction dated Wednesday, September 16th. The shares were acquired at an average price of $3.15 per share, for a total transaction of $63,913.50. Following the acquisition, the chief executive officer directly owned 88,535 shares
- 2026-09-15 Adagene Inc. (ADAG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Adagene Inc. (ADAG) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
- 2026-09-10 Adagene Announces that Third Arc Bio Has Selected First Lead Candidate under Amended Strategic Collaboration for Development of Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology Amended terms of agreement include a transition to an integrated asset and technology partnership. SAN DIEGO and SUZHOU, China, Sept.
- 2026-09-09 Adagene Achieves Milestone in Collaboration with Exelixis for Advancement of SAFEbody® Antibody-Drug Conjugate Candidates SAN DIEGO and SUZHOU, China, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced the achievement of a milestone in its ongoing collaboration and license agreement with Exelixis, Inc. (“Exelixis”).
- 2026-08-20 Adagene to Participate in Three Upcoming Investor Conferences SAN DIEGO and SUZHOU, China, Aug. 20, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (Nasdaq: ADAG) a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in three upcoming investor conferences taking place in New York, New York. 2026 Cantor Global Healthcare Conference; New York, NY – September 9-11, 2026 Format: 1x1 Meetings Date/Time: September 11, 2026 Morgan Stanley 24th Annual Global Healthcare Conference; New York, NY – September 14-16, 2026 Format: Fireside Chat and 1x1 Meetings Fireside Chat Date/Time: September 15, 2026, 10:45–11:20 AM (Eastern Time) H.C.